Hedgehog pathway maintains cell survival under stress conditions, and drives drug resistance in lung adenocarcinoma.

In conclusion, this study showed that HH pathway is a survival signaling that drives LAC cell growth under stress conditions, and HHIP is a key regulator to block the induction of HH pathway. Targeting the HH pathway through inhibitors or HHIP thus holds promise to address EGFR-TKI resistance in LAC in clinic. PMID: 27015549 [PubMed - as supplied by publisher]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Related Links:

Conclusion: Our study confirmed the activity and safety of metronomic oral vinorelbine in patients with wild-type local/advanced and metastatic NSCLC unsuitable for treatment with standard i.v. chemotherapy, allowing patients a comfortable home-based therapy, thereby avoiding frequent hospital visits.
Source: In Vivo - Category: Research Authors: Tags: Clinical Studies Source Type: research
lo Tortora Emilio Bria Before the introduction of tyrosine kinase inhibitors (TKIs) for a particular subgroup of patients, despite platinum-based combination chemotherapy, the majority of patients affected by non-small-cell lung cancer (NSCLC) did not live longer than one year. With deeper understanding of tumor molecular biology, treatment of NSCLC has progressively entered the era of treatment customization according to tumor molecular characteristics, as well as histology. All this information allowed the development of personalized molecular targeted therapies. A series of studies have shown that, in some cases, ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Despite the advent of public health initiatives in recent years, North America and Central and Eastern Europe continue to record some of the highest lung cancer incidence rates globally [1]. Non-small cell lung cancer (NSCLC) accounts for an estimated 80 –90% of all lung cancers, with adenocarcinomas representing an increasing healthcare priority across the USA and Europe [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Abstract Mutations in KEAP1 and NFE2L2 (encoding the protein Nrf2) are prevalent in both adenocarcinoma and squamous subtypes of non-small cell lung cancer. The consequence of these mutations is stabilized Nrf2 and chronic induction of several Nrf2 target genes. Here, downregulation of Nrf2 resulted in modest growth inhibition of cells growing in 2D; this was more pronounced in cell lines expressing mutant KEAP1. In contrast, downregulation of Nrf2 caused almost complete regression of established KEAP1-mutant tumors in mice, with little effect on wildtype (WT) KEAP1 tumors. The strong dependency on Nrf2 could be r...
Source: Genomics Proteomics ... - Category: Genetics & Stem Cells Authors: Tags: Cancer Res Source Type: research
Conclusions: ICI induced regression in some tumors with actionable driver alterations, but clinical activity was lower compared with theKRAS group and the lack of response in the ALK group was notable. Patients with actionable tumor alterations should receive targeted therapies and chemotherapy before considering immunotherapy as a single agent.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Lung cancer is the leading global cause of cancer deaths, with non-small cell lung cancer (NSCLC) accounting for 75-85% of all lung cancer cases [1]. Lung adenocarcinoma and squamous cell carcinoma of the lung are the two major histological types of NSCLC. Cigarette smoking is an important risk factor for many types of cancers, including NSCLC, which is understandable because tobacco smoke contains more than 70 known carcinogens that will eventually initiate carcinogenesis [2,3]. In parallel with the mutagenic and cytotoxic effects of these carcinogens, nicotine, the addictive component of tobacco, and its carcinogenic der...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Authors: Tsakonas G, Ekman S Abstract A majority of non-small cell lung cancer (NSCLC), especially adenocarcinomas, harbour at least one oncogenic driver mutation that can potentially be a target for therapy. The treatment of these oncogene-addicted tumors has dramatically changed the outcome of these patients, where tyrosine kinase inhibitors (TKIs) of mutated epidermal growth factor receptor (EGFR) and rearranged anaplastic lymphoma kinase (ALK) have paved the way for a new era of precision cancer medicine. Another paradigm shift in the treatment of NSCLC, as well as numerous other tumor types, has been the intro...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
CONCLUSION: It is concluded that an orchestrated activation of glucose absorption and metabolism towards anaerobic pathways characterize the majority of NSCLC, and this phenotype is strongly linked with an aggressive clinical behavior. This glycolytic addiction of lung cancer cell is revealed as a key therapeutic target. PMID: 28644754 [PubMed - as supplied by publisher]
Source: Experimental Lung Research - Category: Respiratory Medicine Tags: Exp Lung Res Source Type: research
Abstract According to the latest data, lung cancer is one of the most common cancer worldwide, men contributing nearly 21.2% and women 8.6% of all diagnosed cancers. Late detection of tumour drastically reduces the chance for a cure. Thus, it is important to search for candidate biomarkers for screening of early stage nonsmall cell lung carcinoma (NSCLC). Tumour suppressor genes, DLEC1, TUSC4 and MLH1, localized on 3p21 are recognized to play a role in NSCLC carcinogenesis. The aim of this study was to assess the relationship between the DLEC1, TUSC4 and MLH1 mRNA expression, and clinical features of NSCLC patient...
Source: Journal of Genetics - Category: Genetics & Stem Cells Authors: Tags: J Genet Source Type: research
Detection of genetic alterations mastering lung cancer biology provides suitable targets for personalized anti-cancer therapy. In non-small cell lung cancer (NSCLC), activating mutations of EGFR, HER2, BRAF, MET, as well as gene fusions involving ALK, ROS1, RET, the members of NTRK and FGFR families, govern the oncogenic potential of malignant cells. The detection and targeting of those genetic abnormalities have demonstrated major improvement in clinical outcomes. Altogether, genetic alterations suitable of targeted treatments are currently detected in 30-40% of advanced non-small cell lung cancers (mainly adenocarcinomas...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-Tumour Treatment Source Type: research
More News: Addiction | Adenocarcinoma | Cancer | Cancer & Oncology | Gastroschisis Repair | Lung Cancer | Non-Small Cell Lung Cancer | Study